Per Pfeiffer
YOU?
Author Swipe
View article: Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer
Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer Open
Elevated plasma levels of uPAR(I) and suPAR(I-III+II-III) were associated with poor survival in patients with advanced PDAC independent of CA19-9 levels. These biomarkers have a potential prognostic value in this population.
View article: KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts
KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts Open
View article: Utility of peritoneal fluid for multiplexed mRNA profiling of peritoneal metastasis from pancreatic cancer
Utility of peritoneal fluid for multiplexed mRNA profiling of peritoneal metastasis from pancreatic cancer Open
Our data indicate that PF from PM-PC patients is suitable for transcriptomic analysis. Numerous upregulated mRNAs known to play a role in tumour progression were identified. Our data indicate that mRNA profiling may be a clinically useful …
View article: Implementation of Rapid Drug Desensitization in Antineoplastic Drug Therapy in Denmark Using One‐Bag Protocols
Implementation of Rapid Drug Desensitization in Antineoplastic Drug Therapy in Denmark Using One‐Bag Protocols Open
Background Rapid drug desensitization (RDD) is the cornerstone of managing patients with immediate drug hypersensitivity reactions (IDHR) to antineoplastic drugs in Southern Europe and the United States. As the first in Northern Europe, an…
View article: New dosing schedules in pre-treated patients with metastatic colorectal cancer
New dosing schedules in pre-treated patients with metastatic colorectal cancer Open
View article: Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study Open
View article: 60P No liver metastases vs liver metastases in metastatic colorectal cancer (mCRC)
60P No liver metastases vs liver metastases in metastatic colorectal cancer (mCRC) Open
View article: 235P Outcomes of a rectal cancer population treated with capecitabine-based chemoradiation compared with a cohort switched to S-1 for cardiotoxicity
235P Outcomes of a rectal cancer population treated with capecitabine-based chemoradiation compared with a cohort switched to S-1 for cardiotoxicity Open
View article: Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma
Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma Open
Background: The long-term fate of patients treated for resectable gastro-esophageal adenocarcinoma with perioperative chemotherapy outside randomized clinical trials (RCTs) is poorly described. In this national cohort, we report on outcome…
View article: Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma
Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma Open
Introduction Metastatic pancreatic ductal adenocarcinoma (PDAC) is highly lethal. Promoter hypermethylation of SFRP1 (phSFRP1) in cell-free DNA is an established prognostic biomarker in PDAC. We used digital droplet PCR (ddPCR) to examine …
View article: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study Open
View article: Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative Open
This paper outlines proposals for the setup of a European Network for Gastro-Intestinal Cancers (ENGIC) initiative, aiming at promoting and fostering strategic academic clinical trials for gastrointestinal cancers in Europe. We discuss the…
View article: Prevalence and management of immediate drug hypersensitivity observed during antineoplastic drug therapy
Prevalence and management of immediate drug hypersensitivity observed during antineoplastic drug therapy Open
Background: Immediate drug hypersensitivity reactions (IDHRs) complicate the treatment of patients with cancer. Rapid drug desensitization (RDD) is not a standard treatment option in Northern Europe as in Southern Europe and the US. Thus, …
View article: PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer Open
Summary De novo or acquired resistance to chemotherapy is ubiquitous in pancreatic ductal adenocarcinoma (PDAC). SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver …
View article: Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX Open
Objective: To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA) score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of pancreatic d…
View article: The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer
The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer Open
CA19-9 might aid in identifying patients with a high risk of recurrence after primary radical resection. Further studies are needed to validate these findings.
View article: Elevated Levels of Cleaved Soluble Forms of Urokinase-Type Plasminogen Activator Receptor are Associated with Poor Survival in Advanced Pancreatic Cancer
Elevated Levels of Cleaved Soluble Forms of Urokinase-Type Plasminogen Activator Receptor are Associated with Poor Survival in Advanced Pancreatic Cancer Open
View article: Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer
Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer Open
Objective: This clinical trial investigated the safety and efficacy of single-cycle pembrolizumab in patients with localized deficient mismatch repair (dMMR) colon cancer. Background: Neoadjuvant immunotherapy has induced remarkable rates …
View article: Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer Open
View article: Supplementary Data1 from Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Supplementary Data1 from Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer Open
Supplementary methods and results
View article: Data from Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Data from Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer Open
Purpose:IL1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL1 receptor accessory protein (IL1RAP)–targeting antibody with enhanced antibody-de…
View article: Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer Open
Purpose: IL1 pathway upregulation is implicated in pancreatic ductal adenocarcinoma (PDAC) progression, therapy resistance, and survival. Nadunolimab is an IL1 receptor accessory protein (IL1RAP)–targeting antibody with enhanced antibody-d…
View article: Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer Open
Opinion Statement Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal g…
View article: Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study
Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study Open
The Danish Cancer Society, Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, University of Southern Denmark, Dagmar Marshalls Fond, and Agnes and Poul Friis Fond.
View article: Effect of comprehensive geriatric assessment on hospitalizations in older adults with frailty initiating curatively intended oncologic treatment: The PROGNOSIS-RCT study
Effect of comprehensive geriatric assessment on hospitalizations in older adults with frailty initiating curatively intended oncologic treatment: The PROGNOSIS-RCT study Open
In this study, CGA did not significantly reduce the rate of unplanned hospitalizations. Furthermore, no between-group differences were found in treatment adherence, toxicity lead hospitalizations, or treatment completion in older adults wi…
View article: Prediction of overall survival in patients with locally advanced pancreatic cancer using longitudinal diffusion-weighted MRI
Prediction of overall survival in patients with locally advanced pancreatic cancer using longitudinal diffusion-weighted MRI Open
Background and purpose Biomarkers for prediction of outcome in patients with pancreatic cancer are wanted in order to personalize the treatment. This study investigated the value of longitudinal diffusion-weighted magnetic resonance imagin…
View article: Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group Open
View article: Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study Open
PURPOSE Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with standar…
View article: RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Open
Objectives Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an experimental treatment option in peritoneal metastasis from pancreatic cancer (PM-PC). Aims were to examine mRNA profile of fibrosis due to response after systemic c…
View article: Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer – A phase II study
Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer – A phase II study Open